Cosmo (COPN) Panoramica del titolo
Cosmo Pharmaceuticals N.V. si concentra sullo sviluppo e la commercializzazione di prodotti per la gastroenterologia, la dermatologia e l'healthtech a livello mondiale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 2/6 |
Premi
Analisi del rischio
COPN Community Fair Values
Create NarrativeSee what 154 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 100
FV
27.5% sottovalutato sconto intrinseco3k
users have viewed this narrative8users have liked this narrative
0users have commented on this narrative
84users have followed this narrative
Concorrenti di Cosmo N.V.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | CHF 72.50 |
| Massimo di 52 settimane | CHF 129.40 |
| Minimo di 52 settimane | CHF 53.40 |
| Beta | 1.48 |
| Variazione di 1 mese | -11.59% |
| Variazione a 3 mesi | -33.73% |
| Variazione di 1 anno | 30.87% |
| Variazione a 3 anni | 53.44% |
| Variazione a 5 anni | -16.67% |
| Variazione dall'IPO | 225.11% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • May 16
Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months
Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.
Aggiornamento della narrazione • May 11
COPN: CHF 160 Outlook Will Rely On Successful Alopecia Regulatory Filings
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins and future P/E. These changes collectively support a slightly lower fair value estimate and a modestly higher discount rate in their models.Aggiornamento della narrazione • Apr 23
COPN: Higher CHF 160 Outlook Will Depend On Upcoming Alopecia Filing
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions on fair value, revenue growth, profit margins and future P/E that contribute to a higher overall valuation framework. Analyst Commentary While the higher CHF 160 target reflects updated valuation work, bearish analysts still flag several areas where expectations could prove demanding if underlying assumptions do not play out as planned.
Aggiornamento della narrazione • Apr 08
COPN: Recent Share Placement Will Support Improved Margins And Future Earnings Potential
Analysts have adjusted their price target on Cosmo Pharmaceuticals to CHF 140.45 from CHF 147.89, citing updated views on fair value, revenue growth, profit margins and future P/E assumptions. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares on February 3, 2026 (Key Developments).
Aggiornamento della narrazione • Mar 25
COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside
Analysts have lifted their price target on Cosmo Pharmaceuticals from CHF 104.55 to around CHF 123.72, reflecting updated assumptions for higher revenue growth, a different profit margin profile, and a higher future P/E multiple. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares that represent 5.3% of the company's outstanding shares as of February 3, 2026 (Key Developments).Recent updates
Aggiornamento della narrazione • May 16
Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months
Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.Aggiornamento della narrazione • May 11
COPN: CHF 160 Outlook Will Rely On Successful Alopecia Regulatory Filings
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins and future P/E. These changes collectively support a slightly lower fair value estimate and a modestly higher discount rate in their models.Aggiornamento della narrazione • Apr 23
COPN: Higher CHF 160 Outlook Will Depend On Upcoming Alopecia Filing
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions on fair value, revenue growth, profit margins and future P/E that contribute to a higher overall valuation framework. Analyst Commentary While the higher CHF 160 target reflects updated valuation work, bearish analysts still flag several areas where expectations could prove demanding if underlying assumptions do not play out as planned.Aggiornamento della narrazione • Apr 08
COPN: Recent Share Placement Will Support Improved Margins And Future Earnings Potential
Analysts have adjusted their price target on Cosmo Pharmaceuticals to CHF 140.45 from CHF 147.89, citing updated views on fair value, revenue growth, profit margins and future P/E assumptions. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares on February 3, 2026 (Key Developments).Aggiornamento della narrazione • Mar 25
COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside
Analysts have lifted their price target on Cosmo Pharmaceuticals from CHF 104.55 to around CHF 123.72, reflecting updated assumptions for higher revenue growth, a different profit margin profile, and a higher future P/E multiple. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares that represent 5.3% of the company's outstanding shares as of February 3, 2026 (Key Developments).Aggiornamento della narrazione • Mar 10
COPN: Recent Share Placement Will Support Stronger Revenue And Margin Outlook
Analysts have nudged their price target on Cosmo Pharmaceuticals slightly lower to around CHF148 from approximately CHF150, reflecting updated assumptions on fair value, revenue growth and profit margins while keeping future P/E expectations broadly in line with prior views. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares, which represent 5.3% of the company's outstanding shares, on February 3, 2026 (Key Developments).Aggiornamento della narrazione • Feb 24
COPN: Recent Share Placement Will Support Bullish Long Term Outlook
Analysts have trimmed their price target on Cosmo Pharmaceuticals by CHF 0.00 to reflect slightly updated assumptions on revenue growth, profit margins and future P/E, while keeping their overall fair value view effectively unchanged. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares, equal to 5.3% of outstanding shares, on February 3, 2026 (Key Developments).Aggiornamento della narrazione • Feb 10
COPN: EU Acne Approval And Share Placement Will Support Bullish Outlook
Analysts now set their price target for Cosmo Pharmaceuticals closer to €150, up from about €102, citing updated assumptions for revenue growth, profit margins and future P/E, which feed into a higher fair value estimate. What's in the News Cosmo Pharmaceuticals completed a private placement of 937,086 treasury shares, representing 5.3% of its outstanding shares, with a single institutional investor on February 3, 2026.Aggiornamento della narrazione • Jan 26
COPN: EU Acne Launch And Margin Assumptions Will Likely Keep Shares Fairly Valued
Analysts have moderately raised their price target on Cosmo Pharmaceuticals, citing updates to their fair value estimate along with revised assumptions for revenue growth, profit margins and future P/E. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream) following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).Aggiornamento della narrazione • Jan 11
COPN: EU Acne Authorization And Rollout Will Likely Leave Shares Overextended
Analysts have trimmed their price target for Cosmo Pharmaceuticals by roughly €0.46, reflecting slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple in their updated models. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream), following a prior positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).Aggiornamento della narrazione • Dec 24
COPN: EU Acne Approval And Rollout Are Expected To Support Balanced Outlook
Analysts have modestly trimmed their price target for Cosmo Pharmaceuticals by approximately $0.48, reflecting refined assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for the treatment of acne vulgaris in adults and adolescents 12 to under 18 years, with adolescent use limited to facial application only Key Developments Cosmo Pharmaceuticals and Glenmark Pharmaceuticals secure EU wide approval enabling commercialization of Winlevi across 15 countries, including France, Spain, the Netherlands, and the Nordics Key Developments Glenmark prepares to launch Winlevi in a staged rollout across Bulgaria, the Czech Republic, Denmark, Finland, Hungary, Iceland, Norway, Poland, Portugal, Romania, Slovakia, Sweden, and other approved EU markets Key Developments Valuation Changes The Fair Value Estimate has fallen slightly to CHF 98.24 from CHF 98.72, reflecting a modest downward adjustment in intrinsic valuation.Aggiornamento della narrazione • Dec 09
COPN: EU Authorization And Launch Partnership Are Expected To Support Balanced Outlook
Analysts have nudged their price target for Cosmo Pharmaceuticals slightly higher to approximately $98.72 per share from about $98.59, citing expectations for stronger revenue growth that more than offset a modestly lower projected profit margin and valuation multiple. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for treatment of acne vulgaris in adults and adolescents aged 12 to under 18 years, with adolescent use restricted to facial application EU Marketing Authorization Approval follows a positive CHMP opinion issued on August 25, 2025, confirming regulatory momentum for Cosmo Pharmaceuticals dermatology portfolio EU Marketing Authorization Commercial launch of Winlevi to be led by partner Glenmark Pharmaceuticals across 15 European countries, including France, Spain, the Netherlands, and the Nordics, expanding Cosmo Pharmaceuticals geographic reach EU Marketing Authorization Valuation Changes Fair Value Estimate has risen slightly to CHF 98.72 from CHF 98.59 per share, reflecting a marginal upward revision to intrinsic value.Articolo di analisi • Dec 05
Cosmo Pharmaceuticals N.V. (VTX:COPN) Stocks Shoot Up 35% But Its P/E Still Looks Reasonable
The Cosmo Pharmaceuticals N.V. ( VTX:COPN ) share price has done very well over the last month, posting an excellent...Aggiornamento della narrazione • Nov 25
COPN: EU Approval And Expanded Distribution Expected To Drive Share Performance
Analysts have raised their price target for Cosmo Pharmaceuticals from $87.81 to $98.59. They cite updated fair value assessments and recent model adjustments as the reasons for the change.Aggiornamento della narrazione • Sep 04
Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges
Cosmo Pharmaceuticals’ consensus revenue growth forecasts have strengthened and its future P/E valuation has decreased, but despite these more favourable fundamentals, the consensus analyst price target was only marginally reduced from CHF88.37 to CHF87.81. What's in the News Issued FY2025 guidance: total revenues expected between EUR 102 million and EUR 107 million, with recurring revenues of EUR 85 million to EUR 90 million and project-based revenues of EUR 17 million.
Nuova narrazione • Mar 17
Clascoterone Trials Completion And AI Expansion Will Open Future Markets
Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings.Articolo di analisi • Jan 23
Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity
This weeks picks cover the promising product pipeline from a Cosmo Pharmaceutical, how NLBR bank could almost double its revenue and earnings, and why MINISO Group’s aggressive store expansion plans will pay off.Nuova narrazione • Jan 20
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Revenue: €265.7 million, representing a 186% year-over-year increase from €92.8 million in 2023. This includes €185 million in non-recurring revenues from Medtronic linked to the December 2023 expandeArticolo di analisi • Nov 22
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
When you see that almost half of the companies in the Pharmaceuticals industry in Switzerland have price-to-sales...Articolo di analisi • May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
With a price-to-sales (or "P/S") ratio of 12.2x Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be sending very bearish...Articolo di analisi • Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Cosmo Pharmaceuticals N.V.'s ( VTX:COPN ) recent earnings didn't contain any...Articolo di analisi • Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Celebrations may be in order for Cosmo Pharmaceuticals N.V. ( VTX:COPN ) shareholders, with the analysts delivering a...Articolo di analisi • Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Cosmo Pharmaceuticals N.V.'s ( VTX:COPN ) price-to-earnings (or "P/E") ratio of 67x might make it look like a strong...Articolo di analisi • Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week, you might have seen that Cosmo Pharmaceuticals N.V. ( VTX:COPN ) released its interim result to the market...Articolo di analisi • Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) announced strong profits, but the stock was stagnant. We did some digging, and...Rendimenti per gli azionisti
| COPN | CH Pharmaceuticals | CH Mercato | |
|---|---|---|---|
| 7D | -8.7% | -1.0% | 0.6% |
| 1Y | 30.9% | 27.1% | 9.2% |
Ritorno vs Industria: COPN ha superato il Swiss Pharmaceuticals che ha restituito 27.1 % nell'ultimo anno.
Rendimento vs Mercato: COPN ha superato il mercato Swiss che ha restituito 9.2 % nell'ultimo anno.
Volatilità dei prezzi
| COPN volatility | |
|---|---|
| COPN Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.4% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di COPN è stato volatile rispetto al mercato Swiss.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di COPN è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Swiss.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1997 | 325 | Giovanni Di Napoli | www.cosmohealthconfidence.com |
Cosmo Pharmaceuticals N.V. si concentra sullo sviluppo e la commercializzazione di prodotti per la gastroenterologia, la dermatologia e l'healthtech a livello mondiale. L'azienda offre GI Genius, un sistema computerizzato che utilizza l'intelligenza artificiale in tempo reale per individuare le lesioni del colon-retto; Winlevi, un farmaco da prescrizione utilizzato sulla pelle per il trattamento dell'acne vulgaris; Lialda/Mezavant/Mesavancol, una compressa di mesalamina da assumere una volta al giorno, approvata per favorire la remissione della colite ulcerosa attiva da lieve a moderata; Uceris/Cortiment, una formulazione in compresse orali che somministra budesonide direttamente nel lume del colon; Eleview, una composizione iniettabile per consentire agli endoscopisti un'escissione più rapida e meno rischiosa delle lesioni gastrointestinali; Lumeblue, un farmaco diagnostico per la visualizzazione delle lesioni colorettali durante le colonscopie; Aemcolo/Relafalk, un prodotto farmaceutico in compresse approvato per il trattamento della diarrea dei viaggiatori; Byfavo, un sedativo/anestetico benzodiazepinico per via endovenosa. L'azienda sta inoltre sviluppando Breezula, un nuovo inibitore del recettore degli androgeni, in fase di sperimentazione III, che ha come bersaglio i recettori degli androgeni nel cuoio capelluto; Rifamicina 1% clistere, in fase II di sperimentazione clinica per il trattamento della colite ulcerosa distale e della proctite; Colesevelam, che è in fase di studio preclinico per il trattamento della diarrea da acidi biliari; e Cortexolone 17a-valerato-21-propionato, un antagonista orale dei recettori degli androgeni e dei glucocorticoidi che è in fase I di sperimentazione clinica per il trattamento dei tumori solidi, oltre a fornire la tecnologia AI di Cosmo, un sistema di endoscopia intelligente GI Genius.
Cosmo N.V. Riepilogo dei fondamenti
| COPN statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | CHF 1.22b |
| Utili (TTM) | -CHF 3.30m |
| Ricavi(TTM) | CHF 95.31m |
12.3x
Rapporto P/S-355.6x
Rapporto P/ECOPN è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| COPN Conto economico (TTM) | |
|---|---|
| Ricavi | €104.17m |
| Costo del fatturato | €53.62m |
| Profitto lordo | €50.56m |
| Altre spese | €54.16m |
| Utili | -€3.61m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Jul 23, 2026
| Utile per azione (EPS) | -0.22 |
| Margine lordo | 48.53% |
| Margine di profitto netto | -3.46% |
| Rapporto debito/patrimonio netto | 0.06% |
Come si è comportato COPN nel lungo periodo?
Vedi performance storica e confrontoDividendi
2.7%
Rendimento attuale del dividendo-929%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/02 20:09 |
| Prezzo dell'azione a fine giornata | 2026/06/02 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cosmo N.V. è coperta da 11 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Estelle Bétrisey | Berenberg |
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |